U2932 Cells

Unit

5 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Human cells

,

Lymphoma cell lines

Organism

Human

Donor History

Diffuse large B-cell lymphoma activated B-cell type

Growth Properties

Suspension

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% heat-inactivated FBS. Seeding density: 3-5*10^5/ml. Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/U2932-Cells/305482

SKU: 305482 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

The U-2932 cell line is a diffuse large B-cell lymphoma (DLBCL) model that was established from a patient who developed secondary DLBCL following treatment for Hodgkin lymphoma (HL). The cell line exhibits morphological characteristics typical of DLBCL and has been shown to form colonies in nude mice, confirming its tumorigenic potential. U-2932 is derived from ascitic fluid and maintains a B-cell phenotype with a somatically hypermutated immunoglobulin heavy chain (IgH) gene rearrangement. Notably, the cell line is Epstein-Barr virus (EBV) negative, distinguishing it from some other lymphoma-derived cell lines.

Genomic characterization of U-2932 reveals a complex karyotype, including high-level amplifications at chromosomal bands 18q21 and 3q27, regions associated with oncogenic drivers such as BCL-2 and BCL-6, both of which are overexpressed in this cell line. Additionally, the cell line carries a mutation in the tumor suppressor gene p53 at amino acid position 176, with immunohistochemical analysis confirming p53 overexpression. These genetic alterations suggest a role in both tumor progression and potential resistance to chemotherapy.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.